Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 801–900 of 1,002
Husbeck, B., Bhattacharyya, R. S., Feldman, D., & Knox, S. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0056 · Cited by 56
Establishment of the LNCaP Cell Line – The Dawn of an Era for Prostate Cancer Research
Abate-Shen, C. T., & de Almeida, F. N. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1065 · Cited by 48
The transcriptional programme of the androgen receptor ( AR ) in prostate cancer
Lamb, A. D. G., Massie, C. E., & Neal, D. E. (2013) · British Journal of Urology · doi:10.1111/bju.12415 · Cited by 58
Makkonen, H., Jääskeläinen, T. J., Pitkänen-Arsiola, T., Rytinki, M. M., Waltering, K. K., Mättö, M., Visakorpi, T., & Palvimo, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.125 · Cited by 56
“Forced overexpression of AR can transform androgen-dependent prostate cancer cells to androgenindependent ones (Chen et al., 2004).”
BackgroundAndrogen regulation of soluble guanylyl cyclaseα1 mediates prostate cancer cell proliferation
Cai, C., Chen, S. Y., Zheng, Z., Omwancha, J., Lin, M.-F., Balk, S. P., & Shemshedini, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209956 · Cited by 48
“, 2005) and that overexpression of AR converts prostate cancer growth from hormonesensitive to hormone-refractory (Chen et al., 2004).”
BackgroundDNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
D’Antonio, J. M., Griend, D. J. V., & Isaacs, J. T. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0205 · Cited by 56
“When 329 Downloaded from Bioscientifica.com at 12/28/2018 08:56:19PM via free access prostate cancers are placed in an androgen-depleted environment, the most consistent molecular change is a two to fourfold up-regulation of AR expression (Chen et al. 2004, D’Antonio et al. 2008).”
Qiu, T., Grizzle, W. E., Oelschlager, D. K., Shen, X., & Cao, X. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601499 · Cited by 48
Fankhauser, M., Tan, Y., Macintyre, G., Haviv, I., Hong, M. K. H., Nguyen, A., Pedersen, J. S., Costello, A. J., Hovens, C. M., & Corcoran, N. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3483 · Cited by 50
“This is supported by evidence of receptor upregulation and nuclear localisation both in experimental systems and clinical samples, as well as the increased expression of AR regulated transcripts (notably KLK3/PSA) with disease progression, and confirmed by the recent clinical success of second line hormonal agents tha…”
BackgroundCentral Role for PELP1 in Nonandrogenic Activation of the Androgen Receptor in Prostate Cancer
Yang, L., Ravindranathan, P., Ramanan, M., Kapur, P., Hammes, S. R., Hsieh, J., & Raj, G. V. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1101 · Cited by 50
Yang, J., Xie, S., Huang, Y., Ling, M., Liu, J., Ran, Y., Wang, Y., Thrasher, J. B., Berkland, C. J., & Li, B. (2012) · Nanomedicine · doi:10.2217/nnm.12.14 · Cited by 48
Isolation and characterization of circulating tumor cells in prostate cancer
Diamond, E., Lee, G. Y., Akhtar, N., Kirby, B. J., Giannakakou, P., Tagawa, S. T., & Nanus, D. M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00131 · Cited by 52
“AR signaling can continue to stimulate tumor growth in castrate patients via intra-tumoral androgen synthesis or constitutive AR activation-independent of ligand binding (Chen et al., 2004).”
BackgroundQi, W., Morales, C., Cooke, L. S., Johnson, B., Somer, B. G., & Mahadevan, D. (2015) · Oncotarget · doi:10.18632/oncotarget.5659 · Cited by 54
“Several mechanisms including androgen receptor (AR) mutations, AR or its co-regulator proteins overexpression, intraprostatic androgen synthesis up-regulation and gene fusions have been proposed to result in CRPC progression, which suggests AR signaling remains a critical factor for the growth and survival of the horm…”
BackgroundRamalingam, S., Ramamurthy, V. P., & Njar, V. C. O. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.07.006 · Cited by 57
Role of steroid receptor and coregulator mutations in hormone-dependent cancers
Groner, A. C., & Brown, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88885 · Cited by 51
“Many mechanisms contributing to endocrine therapy resistance in PCa and BCa have been proposed.”
InfluentialA combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor
Licciardello, M. P., Ringler, A., Markt, P., Klepsch, F., Lardeau, C.-H., Sdelci, S., Schirghuber, E., Müller, A. C., Caldera, M., Wagner, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2382 · Cited by 54
Androgen Receptor in Breast Cancer: From Bench to Bedside
Chen, M., Yang, Y., Xu, K., Li, L., Huang, J., & Qiu, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00573 · Cited by 50
Zou, J. X., Zhong, Z., Shi, X.-B., Tepper, C. G., White, R. D., Kung, H.-J., & Chen, H.-W. (2006) · The Prostate · doi:10.1002/pros.20477 · Cited by 53
Phase II study of transdermal estradiol in androgen‐independent prostate carcinoma
Bland, L. B., Garzotto, M. G., DeLoughery, T. G., Ryan, C. W., Schuff, K. G., Wersinger, E. M., Lemmon, D., & Beer, T. M. (2005) · Cancer · doi:10.1002/cncr.20857 · Cited by 49
Raf‐1 expression may influence progression to androgen insensitive prostate cancer
Mukherjee, R., Bartlett, J. M. S., Krishna, N. S., Underwood, M. A., & Edwards, J. (2005) · The Prostate · doi:10.1002/pros.20211 · Cited by 57
“This process activates the AR in the absence of androgens or sensitizes the AR to low levels of circulating adrenal androgens [5].”
NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells
Gordon, C. A., Gulzar, Z. G., & Brooks, J. D. (2015) · The Prostate · doi:10.1002/pros.22938 · Cited by 53
“Androgen receptor (AR), also commonly perturbed in prostate cancer, is often overexpressed in castration resistant prostate cancer [5,27–33] and may be part of some of the same signaling networks as NUSAP1.”
BackgroundMultiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors
Creighton, C. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001816 · Cited by 48
“[12] treatment of LNCaP prostate cells with R1881 559 761 1%”
MethodInfluentialMorken, J. D., Packer, A., Everett, R. A., Nagy, J. D., & Kuang, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3162 · Cited by 47
“It has been demonstrated that overexpression of wild-type AR is adequate to fully transform a CS tumor into a CR tumor (24).”
BackgroundThe CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor
Kasina, S., & Macoska, J. A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.12.015 · Cited by 52
“…producing increased AR activity, and chromatin remodeling conducive to more efficient transcription of ARregulated genes, in such tumors [Chen et al., 2002; Cronauer et al., 2003; Culig et al., 1998; Debes and Tindall, 2002; Jia et al., 2006; Pienta and Bradley, 2006; Scher et al.,…”
BackgroundDeveloping imaging strategies for castration resistant prostate cancer
Fox, J. J., Morris, M. J., Larson, S. M., Schöder, H. M., & Scher, H. I. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.572914 · Cited by 49
“The hallmark of castration resistant prostate cancer (CRPC) is evidence of tumor growth despite castrate levels of serum androgens [3].”
BackgroundTailoring Peptidomimetics for Targeting Protein–Protein Interactions
Akram, O. N., DeGraff, D. J., Sheehan, J. H., Tilley, W. D., Matusik, R. J., Ahn, J., & Raj, G. V. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0611 · Cited by 52
“Maintenance of AR activity following androgen ablation can occur due to amplification of AR, deregulation of the expression of AR coregulators, intratumoral production of androgens, gain-of-function AR mutations, and indirect AR activation by growth factors, cytokines (15).”
BackgroundNadiminty, N., & Gao, A. C. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0771-3 · Cited by 55
“array showed increased AR mRNA in hormone-refractory prostate tumor xenografts compared to their hormonesensitive parental cells [4].”
BackgroundKobayashi, T., Inoue, T., Kamba, T., & Ogawa, O. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140815615 · Cited by 54
“High AR expression in CRPC is reproducible in some experimental models based on cell lines [39], cell line-based xenograft lines [40,41], and”
BackgroundInfluentialAllioli, N., Vincent, S., Vlaeminck‐Guillem, V., Decaussin‐Petrucci, M., Ragage, F., Ruffion, A., & Samarut, J. (2011) · The Prostate · doi:10.1002/pros.21340 · Cited by 47
“The steroid nuclear receptor AR plays a crucial role in both androgen-dependent prostate cancer development and its progression to an advanced hormone-refractory stage [5].”
BackgroundMeng, D., Yang, S., Wan, X., Zhang, Y., Huang, W., Zhao, P., Li, T., Wang, L., Huang, Y., Li, T., et al. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.01.018 · Cited by 51
Obinata, D., Takayama, K., Takahashi, S., & Inoue, S. (2017) · Cancers · doi:10.3390/cancers9030022 · Cited by 53
“Using AR-overexpressing cells, an in vitro study showed that first generation anti-androgen drugs promote AR nuclear translocation, DNA binding and co-activator recruitment [17].”
BackgroundProstate tumor neuroendocrine differentiation via EMT: The road less traveled
Dicken, H., Hensley, P. J., & Kyprianou, N. (2018) · Asian journal of urology · doi:10.1016/j.ajur.2018.11.001 · Cited by 54
Ko, S., Shi, L., Kim, S., Song, C. S., & Chatterjee, B. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0332 · Cited by 47
Development of the VCaP androgen-independent model of prostate cancer
Loberg, R. D., John, L. S., Day, L. L., Neeley, C. K., & Pienta, K. J. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.11.005 · Cited by 47
“[5] Chen CD, Welsbie DS, Tran C, et al.”
BackgroundSirotnak, F. M., She, Y., Khokhar, N. Z., Hayes, P., Gerald, W. L., & Scher, H. I. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20051 · Cited by 48
“The reason for these differences in AR gene expression found in this study [19] and our own are not known.”
BackgroundAdvances with androgen deprivation therapy for prostate cancer
Yu, E.-M., & Aragon‐Ching, J. B. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2033210 · Cited by 51
Galsky, M. D., Small, A., Tsao, C., & Oh, W. K. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21141 · Cited by 56
“AR overexpression shortens tumor latency in castrate mice and confers resistance to bicalutamide.(54) MDV3100 is a novel antiandrogen selected for clinical development based on significant preclinical activity, even in the setting of AR amplification.”
BackgroundGrossi, V., Lucarelli, G. T., Forte, G., Peserico, A., Matrone, A., Germani, A., Rutigliano, M., Stella, A., Bagnulo, R., Loconte, D. C., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1091910 · Cited by 46
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Yin, L., Hu, Q., & Hartmann, R. W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713958 · Cited by 49
“However, after the progression to CRPC, in which AR is highly over-expressed [48], the first generation AR antagonists, such as Flutamide and Bicalutamide, are impotent largely because of the relatively lower affinity compared to dihydrotestosterone (DHT)—the natural substrate of AR and the most potent androgen.”
BackgroundAndrogen Receptor: Past, Present and Future
Schmidt, L. J., & Tindall, D. J. (2013) · Current Drug Targets · doi:10.2174/1389450111314040002 · Cited by 47
“In vivo studies have shown that overexpression of AR mRNA through retroviral infection of LNCaP or LAPC4 PCa cells resulted in tumor formation in castrated mice [40]; this was abrogated by shRNA to AR.”
BackgroundCooper, C. S., Campbell, C., & Jhavar, S. G. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0946 · Cited by 47
“In an experiment that was key to understanding the mechanism of the development of CRPC, Chen et al”
MethodInterleukin‐4 stimulates androgen‐independent growth in LNCaP human prostate cancer cells
Lee, S. O., Pinder, E., Chun, J. Y., Lou, W., Sun, M., & Gao, A. C. (2007) · The Prostate · doi:10.1002/pros.20691 · Cited by 50
Salvati, M., Balog, A., Wei, D. D., Pickering, D., Attar, R. M., Geng, J., Rizzo, C. A., Hunt, J. T., Gottardis, M. M., Weinmann, R. S., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.051 · Cited by 46
Fujimoto, N., Kubo, T., Inatomi, H., Bui, H. T. T., Shiota, M., Sho, T., & Matsumoto, T. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.23 · Cited by 48
Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function
Comstock, C. E. S., Augello, M. A., Schiewer, M. J., Karch, J. M., Burd, C. J., Ertel, A., Knudsen, E. S., Jessen, W. J., Aronow, B. J., & Knudsen, K. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.170720 · Cited by 47
Mashima, T., Okabe, S., & Seimiya, H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064790 · Cited by 47
“Although the recurrent tumors are often resistant to standard AR-targeting agents, which deprive androgens or block androgen-AR interaction, AR-mediated signaling still plays a key role in the development and maintenance of HRPC in most cases (Grossmann et al., 2001; Chen et al., 2004; Taplin and Balk, 2004).”
BackgroundExploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer
Martin, S. K., & Kyprianou, N. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.03.001 · Cited by 54
Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer
Shukla, K. K., Misra, S., Pareek, P., Mishra, V., Singhal, B., & Sharma, P. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.019 · Cited by 46
Takayama, K., Kosaka, T., Suzuki, T., Hongo, H., Oya, M., Fujimura, T., Suzuki, Y., & Inoue, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23974-4 · Cited by 46
Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist
Song, C.-H., Yang, S., Park, E., Cho, S. H., Gong, E., Khadka, D. B., Cho, W., & Lee, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379107 · Cited by 46
Calpain‐mediated androgen receptor breakdown in apoptotic prostate cancer cells
Yang, H., Murthy, S., Sarkar, F. H., Sheng, S., Reddy, G. P., & Dou, Q. P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21565 · Cited by 47
“As a result, these hormone-independent cancer cells are very sensitive to low or no androgen environments, and are responsive to a broad range of ligands such as growth factors, other steroid hormones, anti-androgens, etc. (Culig et al., 1994; Chen et al., 2004).”
BackgroundWysocka, J., Milne, T. A., & Allis, C. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.022 · Cited by 45
“Increased expression of androgen receptor and activation of its target genes appears to be an important mechanism for the conversion of metastatic prostate cancer into a treatment-resistant form (Chen et al., 2004).”
BackgroundTargeting the Androgen Receptor in Prostate Cancer — A Resilient Foe
Nelson, P. S. (2014) · New England Journal of Medicine · doi:10.1056/nejme1409306 · Cited by 48
Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance
Li, C., Cheng, D., & Li, P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1542811 · Cited by 73
“Additionally, RNA modi fi cations (such as m6A methylation) have also been shown to play a signi fi cant role in the stability and translation ef fi ciency of AR mRNA, providing a foundation for potential therapeutic targets (17, 18).”
Komiya, A., Yasuda, K., Watanabe, A., Fujiuchi, Y., Tsuzuki, T., & Fuse, H. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.69 · Cited by 44
“The high levels of AR expression and the development of hypersensitive receptors have been recognized as a feature associated with the development of CRPC (13,16).”
Gluschnaider, U., Hidas, G., Cojocaru, G., Yutkin, V., Ben‐Neriah, Y., & Pikarsky, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009060 · Cited by 48
“. AR signaling is known to regulate normal, benign and cancerous prostate cells in various processes (e.g. differentiation and proliferation). In addition, there are observations indicating that AR expression is oncogenic in prostate epithelium and promotes progression to androgen independence”
BackgroundMolecular epidemiology and its current clinical use in cancer management
Hartman, M., Loy, E. Y., Ku, C., & Chia, K. S. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70005-x · Cited by 44
Circulating steroid hormone variations throughout different stages of prostate cancer
Snaterse, G., Visser, J. A., Arlt, W., & Hofland, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0155 · Cited by 50
Shah, K., Gagliano, T., Garland, L., O’Hanlon, T., Bortolotti, D., Gentili, V., Rizzo, R., Giamas, G., & Dean, M. C. (2020) · Oncogene · doi:10.1038/s41388-020-01429-2 · Cited by 50
He, Y., Hwang, D., Ponnusamy, S., Thiyagarajan, T., Mohler, M. L., Narayanan, R., & Miller, D. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00439 · Cited by 44
Thompson, V. C., Day, T. K., Bianco‐Miotto, T., Selth, L. A., Han, G., Thomas, M., Buchanan, G., Scher, H. I., Nelson, C. C., BioResource, T. A. P. C., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26414 · Cited by 47
“Many studies have identified and characterized AR target genes in the prostate(20) but in general have not been able to discriminate those that are responsible for AR-mediated tumorigenesis from those that are simply altered due to progression-mediated changes in AR action.(21) The ARE231G model of AR-driven oncogenes…”
BackgroundGravina, G. L., Festuccia, C., Millimaggi, D., Dolo, V., Tombolini, V., de Vito, M., Vicentini, C., & Bologna, M. (2008) · The Prostate · doi:10.1002/pros.20748 · Cited by 44
“The loss of AR expression in androgen-independent cells appears to occur at the transcriptional level [6] and does not involve either deletional or mutational mechanisms [7,8].”
Ricciardelli, C., Jackson, M. W., Choong, C. S., Stahl, J., Marshall, V. R., Horsfall, D. J., & Tilley, W. D. (2008) · The Prostate · doi:10.1002/pros.20747 · Cited by 50
“Moreover, the AR has recently been implicated in the progression of prostate cancer to a hormone refractory state [20].”
BackgroundResultThe Role of Stress Proteins in Prostate Cancer
So, A., Hadaschik, B. A., Sowery, R. D., & Gleave, M. E. (2007) · Current Genomics · doi:10.2174/138920207781386951 · Cited by 48
“ca growth factor pathways [7-11], as well as ligand-independent androgen receptor (AR) transactivation [12-15].”
BackgroundSynthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors
Moreira, V. M., Vasaitis, T. S., Njar, V. C. O., & Salvador, J. A. R. (2007) · Steroids · doi:10.1016/j.steroids.2007.08.004 · Cited by 51
“Mechanisms that may mediate this adaptation include AR amplification, ARmutation, alterations in the balance between transcriptional coactivators and corepressors, and activation of signal transduction pathways that by-pass the AR [12,13].”
BackgroundKaulfuß, S., Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S., Neesen, J., Bubendorf, L., Glass, A. G., Jarry, H., Auber, B., et al. (2008) · Molecular Endocrinology · doi:10.1210/me.2006-0546 · Cited by 44
Gleave, M. E., Miyake, H., & Chi, K. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0098-0 · Cited by 44
“Increased expression of bcl-2 [27, 59], androgen receptor [12], clusterin [40, 49], IGFBP-5 [51], IGFBP-2 [41] and Hsp27 [60] after castration help confer androgen resistance and represent adaptive responses by malignant cells to activate survival and mitogenic pathways to compensate for androgen withdrawal (Fig.”
BackgroundProstate Cancer Stem Cells: A Target for New Therapies
Maitland, N. J., Bryce, S. D., Stower, M. J., & Collins, A. T. (2007) · Springer eBooks · doi:10.1007/2789_2007_050 · Cited by 51
Li, W., Cavasotto, C. N., Cardozo, T. J., Ha, S., Dang, T., Taneja, S. S., Logan, S. K., & Garabedian, M. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0134 · Cited by 50
Bioinformatics for Cancer Management in the Post-Genome Era
Katoh, M., & Katoh, M. (2006) · Technology in Cancer Research & Treatment · doi:10.1177/153303460600500208 · Cited by 51
Germain, L., Lafront, C., Paquette, V., Neveu, B., Paquette, J., Pouliot, F., & Audet‐Walsh, É. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00726-1 · Cited by 52
Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
Chetta, P., Sriram, R., & Zadra, G. (2023) · Cancers · doi:10.3390/cancers15133473 · Cited by 51
Nyquist, M. D., & Dehm, S. M. (2013) · Hormones and Cancer · doi:10.1007/s12672-013-0131-4 · Cited by 50
“For example, AR gene amplification leads to overexpression of AR protein, which sensitizes PCa cells to castrate levels of androgens, and can also elicit inappropriate agonist responses to antiandrogens such as bicalutamide [28].”
Kokontis, J. M., Lin, H., Jiang, S. S., Lin, C., Fukuchi, J., Hiipakka, R. A., Chung, C., Chan, T.-M., Liao, S., Chang, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109170 · Cited by 48
“Increase in AR mRNA and protein is observed in CRPC tumors compared to the primary prostate tumors [5,6].”
BackgroundAndrogen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
Kim, W. K., & Ryan, C. J. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0188-2 · Cited by 45
Targeting the Androgen Receptor with Steroid Conjugates
Levine, P. M., Garabedian, M. J., & Kirshenbaum, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500101h · Cited by 50
Li, H., Xie, N., Chen, R., Verreault, M., Fazli, L., Gleave, M. E., Barbier, O., & Dong, X. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1518 · Cited by 49
“Several 51 possible mechanisms that restore AR signaling have been defined including AR gene 52 overexpression and amplification (5), AR gain-of-function mutations in the LBD with a more 53 promiscuous affinity to other ligands (6), aberrant AR gene splicing encoding constitutively 54 active forms of AR (7, 8), and ph…”
BackgroundSelf-citationZhai, G., Shu, T., Xia, Y., Jin, X., He, J., & Yin, Z. (2017) · 中国科学通报:英文版 · doi:10.1016/j.scib.2017.01.007 · Cited by 43
“Previous studies have established an important role for AR and SOX9A in the development of multiple tissues [14,15,22].”
BackgroundCLDN 8 , an androgen‐regulated gene, promotes prostate cancer cell proliferation and migration
Ashikari, D., Takayama, K., Obinata, D., Takahashi, S., & Inoue, S. (2017) · Cancer Science · doi:10.1111/cas.13269 · Cited by 48
Sachan, R., Kundu, A. B., Jeon, Y., Choi, W. S., Yoon, K., Kim, I. S., Kwak, J. H., & Kim, H. S. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.10.012 · Cited by 43
He, Y., Hwang, D., Ponnusamy, S., Thiyagarajan, T., Mohler, M. L., Narayanan, R., & Miller, D. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00943 · Cited by 43
Yu, S., Jia, L., Zhang, Y., Wu, D., Xu, Z., Ng, C., To, K. K. W., Huang, Y., & Chan, F. L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.006 · Cited by 45
“We also observed that AR protein expression was increased in the LNCaP-BC cells, a pattern consistent with several clinical studies showing that amplification and overexpression of AR gene is a common event associated with the advanced progression of hormone-refractory or castration-resistant [46–48], antiandrogenresi…”
ResultSun, A., Tang, J., Terranova, P. F., Zhang, X., Thrasher, J. B., & Li, B. (2009) · International Journal of Cancer · doi:10.1002/ijc.24778 · Cited by 44
“Clinically, nearly all prostate cancers including castration-resistant diseases retain a functional androgen receptor (AR) signaling pathway, which is the most critical factor in prostate cancer progression.(1) Current evidence favors a mechanism by which aberrant activation of intracellular signal transduction pathwa…”
BackgroundRedefining hormone resistance in prostate cancer
Hoimes, C. J., & Kelly, W. K. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009356433 · Cited by 47
“Elevated AR protein expression is necessary and sufficient to confer resistance to antiandrogen therapy in murine xenografts and 112 http://tam.sagepub.com sensitizes prostate cancer cells to respond to low levels of androgen ligand [Chen et al. 2004].”
BackgroundInfluentialStan, S. D., & Singh, S. V. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0512 · Cited by 43
Modulation of Androgen Receptor Transactivation by FoxH1
Chen, G., Nomura, M., Morinaga, H., Matsubara, E., Okabe, T., Goto, K., Yanase, T., Zheng, H., Lu, J., & Nawata, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506147200 · Cited by 45
Tang, S., Sethunath, V., Metaferia, N. Y., Nogueira, M. F., Gallant, D. S., Garner, E. R., Lairson, L. A., Penney, C. M., Li, J., Gelbard, M. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110417 · Cited by 46
Conformational dynamics of androgen receptors bound to agonists and antagonists
Gim, H. J., Park, J., Jung, M. E., & Houk, K. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-94707-2 · Cited by 47
Mardilovich, K., Gabrielsen, M., McGarry, L., Orange, C., Patel, R., Shanks, E. J., Edwards, J., & Olson, M. F. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0447 · Cited by 42
“Recent research has shown that CRPC cells are reliant on AR signaling, and adapt to hormone depletion therapy by increasing AR expression and/or upregulating androgen production (43, 44).”
BackgroundInhibition of prostate cancer cell growth by second-site androgen receptor antagonists
Joseph, J. D., Wittmann, B. M., Dwyer, M. A., Cui, H. N., Dye, D. A., McDonnell, D. P., & Norris, J. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900185106 · Cited by 42
“0 M Csx compared with the 10 M that was used in those studies, suggesting that high concentrations of Csx are required for efficient delivery of AR to DNA (8).”
BackgroundInfluentialGnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer
Labrie, F. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0165 · Cited by 43
“In preclinical models, overexpression of AR shortens the response duration and makes the tumors resistant to bicalutamide (Chen et al. 2004).”
BackgroundThe Changing Natural History of Metastatic Prostate Cancer
Alva, A. S., & Hussain, M. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318281197e · Cited by 44
“Gain-offunction AR mutations lead to promiscuous activation of AR by nonandrogen ligands.(42,43) Up-regulation and modification of steroid receptor coactivators(44,45) and constitutive AR activation by AR splice variants(46,47) could exert similar effects.”
BackgroundMohammad, O. S., Nyquist, M. D., Schweizer, M. T., Balk, S. P., Corey, E., Plymate, S. R., Nelson, P. S., & Mostaghel, E. A. (2017) · Cancers · doi:10.3390/cancers9120166 · Cited by 44
“Restoration of full length AR expression and signaling in a xenograft model was both necessary and sufficient to drive progression from androgen-dependent to castration resistant growth, sensitizing cells to proliferate in 80% lower androgen concentrations [33].”
BackgroundYe, M., Tian, H., Lin, S., Mo, J., Li, Z., Chen, X., & Liu, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12032 · Cited by 47
Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
Scaravilli, M., Koivukoski, S., & Latonen, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.623809 · Cited by 43
“The AR also plays a crucial role in the development of castration-resistant disease (Chen et al., 2004) and the majority of CRPC cases remain dependent on AR signaling.”
BackgroundGleave, M. E., & CHI, K. N. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1359.001 · Cited by 47
Androgen Receptor as a Therapeutic Target for Androgen Independent Prostate Cancer
Sharifi, N., & Farrar, W. L. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200603000-00013 · Cited by 43
“Gene expression analysis comparing 7 androgen-dependent prostate cancer cell lines and their androgen-independent derivatives selected in an androgen-deprived mouse xenograft model suggests that the only consistent gene expression difference between the two is increased AR expression.(17) It has been suggested from th…”
BackgroundBaek, K. H., Hong, M. E., Jung, Y. Y., Lee, C. H., Lee, T. J., Park, E. S., Kim, M. K., Yoo, J. H., & Lee, S. W. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.1.50 · Cited by 47
“Any primary molecular event that alters AR activity could thus increase AR mRNA levels, suggesting a common final pathway for escape from standard hormone therapy [18].”
BackgroundChen, G., Goto, Y., Sakamoto, R., Tanaka, K., Matsubara, E., Nakamura, M., Zheng, H., Lu, J., Takayanagi, R., & Nomura, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.065 · Cited by 44
“Although transition from androgen-dependence to androgen-independence is generally believed to be a critical step in the progression of prostate cancer, mechanisms underlying this switch are not well understood [1,3].”
The University of North Carolina at Chapel Hill University Libraries (2010) · PubMed · doi:10.17615/40wq-1140 · Cited by 48
Prostate cancer stem cells: Are they androgen-responsive?
Oldridge, E. E., Pellacani, D., Collins, A. T., & Maitland, N. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.008 · Cited by 61
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.